The s100β Levels in Patients With Mild Brain Injury.

Sponsor
Sumei Lu (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06131242
Collaborator
(none)
494
33.7

Study Details

Study Description

Brief Summary

Mild traumatic brain injury (TBI) accounts for the majority of TBI. At present, whether TBI has traumatic intracranial lession is mainly diagnosed by computed tomography (CT), while only 5% of mild TBI has positive CT results. The risk stratification method for patients with mild TBI is needed to reduce unnecessary CT use and reduce medical costs.

S100β is a protein in glial cells and can be used as a biomarker of brain injury. S100β is showed to have the clinical and economic value in ruling out traumatic intracranial lesions in mild TBI patients in Europe and the United States. However, it was showed to have difference between races, and there lacks systematic research data from Chinese population. In addition, if it is used for emergency departments, it is necessary to evaluate new rapid detection methods.

This study is based on a novel fast S100β test. The reference intervals of S100β in Chinese adults will be established. Further, evaluation of S100β in diagnosis of traumatic intracranial lesions in acute mild TBI will be conducted from the perspective of clinical and economic value in China, which will provide data for screening of low-risk TBI patients and avoiding unnecessary CT use in clinical practice.

Condition or Disease Intervention/Treatment Phase
  • Other: It is an observational study

Study Design

Study Type:
Observational
Anticipated Enrollment :
494 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Application Value of Serum S100β in Acute Mild Traumatic Brain Injury.
Anticipated Study Start Date :
Nov 9, 2023
Anticipated Primary Completion Date :
Apr 30, 2026
Anticipated Study Completion Date :
Aug 31, 2026

Arms and Interventions

Arm Intervention/Treatment
According to age, the group was divided into 18-45, 45-65, and > 65 years old.

Other: It is an observational study
It is an observational study

Outcome Measures

Primary Outcome Measures

  1. The serum s100β levels [2024.6-2026.6]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Study on healthy people: Apparently healthy people >18 years old who came to our hospital for physical examination.

  2. Study of emergency trauma patients: 1) Emergency trauma patients at least 18 years old with suspected brain injury; 2) Glasgow Coma Score 13-15 (patients with mild traumatic brain injury); 3) Closed head trauma; 4) Clinical judgment of patients requiring craniocerebral CT examination.

Exclusion Criteria:
  1. Healthy population study: stroke history, trauma, surgery, mental illness, senile dementia, cognitive impairment, and tumor patients within 3 months.

  2. Study of emergency trauma patients: 1) neurological or psychiatric history, 2) intellectual disabilities, 3) alcohol or drug addiction (trauma after drinking was eligible for inclusion, but alcohol consumption was recorded), 4) brain tumor patients, 5) time of trauma was not available, and 6) patients whose clinical conditions were deemed unsuitable for participation in the trial.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Sumei Lu

Investigators

  • Study Director: Sumei Lu,

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sumei Lu, Principal Investigator, Qianfoshan Hospital
ClinicalTrials.gov Identifier:
NCT06131242
Other Study ID Numbers:
  • YXLL-KY-2023(109)
First Posted:
Nov 14, 2023
Last Update Posted:
Nov 18, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 18, 2023